Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Refine search result
1 - 15 of 15
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Baskin, Berivan
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medicinsk genetik och genomik. Hosp Sick Children, Dept Pediat Lab Med, Toronto, Canada.
    Kalia, Lorraine V.
    Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, Canada; Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, Canada; Univ Toronto, Univ Hlth Network, Div Neurol, Dept Med, Toronto, Canada.
    Banwell, Brenda L.
    Univ Philadelphia, Perelman Sch Med, Childrens Hosp Philadelphia, Philadelphia, USA.
    Ray, Peter N.
    Hosp Sick Children, Dept Pediat Lab Med, Toronto, Canada; Univ Toronto, Dept Mol Genet, Toronto, Canada.
    Yoon, Grace
    Univ Toronto, Hosp Sick Children, Dept Pediat, Div Clin & Metab Genet, Toronto, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat, Div Neurol, Toronto, Canada.
    Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism2017In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 32, no 12, p. 1792-1794Article in journal (Refereed)
  • 2.
    Larsson, Susanna C.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Orthopaedics.
    Singleton, Andrew B
    Nalls, Mike A
    Richards, J Brent
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.2017In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 32, no 8, p. 1249-1252Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Observational studies have found that relative to healthy controls, patients with Parkinson's disease have lower circulating concentrations of 25-hydroxyvitamin D, a clinical biomarker of vitamin D status. However, the causality of this association is uncertain. We undertook a Mendelian randomization study to investigate whether genetically decreased 25-hydroxyvitamin D concentrations are associated with PD to minimize confounding and prevent bias because of reverse causation.

    METHODS: As instrumental variables for the Mendelian randomization analysis, we used 4 single-nucleotide polymorphisms that affect 25-hydroxyvitamin D concentrations (rs2282679 in GC, rs12785878 near DHCR7, rs10741657 near CYP2R1, and rs6013897 near CYP24A1). Summary effect size estimates of the 4 single-nucleotide polymorphisms on PD were obtained from the International Parkinson's Disease Genomics Consortium (including 5333 PD cases and 12,019 controls). The estimates of the 4 single-nucleotide polymorphisms were combined using an inverse-variance weighted meta-analysis.

    RESULTS: Of the 4 single-nucleotide polymorphisms associated with 25-hydroxyvitamin D concentrations, one (rs6013897 in CYP24A1) was associated with PD (odds ratio per 25-hydroxyvitamin D-decreasing allele, 1.09; 95% confidence interval, 1.02-1.16; P = 0.008), whereas no association was observed with the other 3 single-nucleotide polymorphisms (P > 0.23). The odds ratio of PD per genetically predicted 10% lower 25-hydroxyvitamin D concentration, based on the 4 single-nucleotide polymorphisms, was 0.98 (95% confidence interval, 0.93-1.04; P = 0.56).

    CONCLUSIONS: This Mendelian randomization study provides no clear support that lowered 25-hydroxyvitamin D concentration is causally associated with risk of PD. © 2017 International Parkinson and Movement Disorder Society.

    Download full text (pdf)
    fulltext
  • 3. Marrinan, Sarah L
    et al.
    Otiker, Tal
    Vasist, Lakshmi S
    Gibson, Rachel A
    Sarai, Bhopinder K
    Barton, Matthew E
    Richards, Duncan B
    Hellström, Per M.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology.
    Nyholm, Dag
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Dukes, George E
    Burn, David J
    A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.2018In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 33, no 2, p. 329-332Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.

    METHODS: Phase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50 mg once-daily (n = 38) or placebo (n = 20) for 7 to 9 days.

    RESULTS: l-dopa exposure was similar with coadministration of camicinal compared to placebo. Median time to maximum l-dopa concentration was reduced, indicating more rapid absorption of l-dopa. Camicinal resulted in significant reduction in OFF time (-2.31 hours; 95% confidence interval: -3.71, -0.90), significant increase in ON time (+1.88 hours; 95% confidence interval: 0.28, 3.48) per day, and significant decrease in mean total MDS-UPDRS score (-12.5; 95% confidence interval: -19.67, -5.29). Camicinal treatment was generally well tolerated.

    CONCLUSIONS: PD symptom improvement with camicinal occurred in parallel with more rapid absorption of l-dopa. This study provides evidence of an improvement of the motor response to l-dopa in people with PD treated with camicinal 50 mg once-daily compared with placebo, which will require further evaluation.

    Download full text (pdf)
    fulltext
  • 4.
    Martino, Davide
    et al.
    Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.;Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada..
    Brander, Gustaf
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Science for Life Laboratory, SciLifeLab. Stockholm Hlth Care Serv, Stockholm, Region Stockhol, Sweden.;Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden..
    Svenningsson, Per
    Stockholm Hlth Care Serv, Stockholm, Region Stockhol, Sweden.;Karolinska Inst, Dept Clin Neurosci, Neuro Div, Stockholm, Sweden..
    Larsson, Henrik
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Örebro Univ, Sch Med Sci, Örebro, Sweden..
    Fernandez de la Cruz, Lorena
    Stockholm Hlth Care Serv, Stockholm, Region Stockhol, Sweden.;Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden..
    Association and Familial Coaggregation of Idiopathic Dystonia with Psychiatric Outcomes2020In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 35, no 12, p. 2270-2278Article in journal (Refereed)
    Abstract [en]

    Background Psychiatric comorbidities are common and major determinants of quality of life in idiopathic dystonia. Their prevalence estimates from service-based studies are heterogeneous. Objective We explored the association between idiopathic dystonia and depressive disorders, anxiety disorders, suicide attempts, and death by suicide using Swedish population-based registers. Methods Diagnoses of idiopathic dystonia and psychiatric outcomes from inpatient and outpatient specialist services (1997-2013) were collected from the National Patient Register and the Cause of Death Register. Familial associations were explored using the Multi-Generation Register. Adjusted logistic regression analyses measured associations with psychiatric disorders in individuals with dystonia compared with general population individuals and their unaffected siblings, as well as in full siblings of individuals with dystonia compared with full siblings of unaffected individuals. Results Individuals with dystonia were more likely than those without to have a diagnosis of depressive disorder (adjusted odds ratio = 2.00, 95% confidence interval: 1.77-2.26), anxiety disorder (adjusted odds ratio = 2.13, 95% confidence interval: 1.90-2.39), and suicide attempts/death by suicide combined (adjusted odds ratio = 1.80, 95% confidence interval: 1.50-2.17), with odds higher in most idiopathic dystonia forms. In the full sibling comparison, estimates followed the same pattern, with overall attenuated magnitude. Full siblings of individuals with dystonia had higher likelihood of depressive or anxiety disorders and suicide attempts/death by suicide combined compared with siblings of individuals without dystonia. Conclusions Different forms of idiopathic dystonia confirm its association with increased risk for depressive and anxiety disorders and suicide attempts. Familial coaggregation of dystonia and these psychiatric comorbidities supports shared genetic and extragenetic factors. (c) 2020 International Parkinson and Movement Disorder Society

  • 5.
    Mataix-Cols, David
    et al.
    Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden.;Stockholm Hlth Care Serv, Stockholm, Sweden..
    Brander, Gustaf
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Science for Life Laboratory, SciLifeLab. Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden.;Stockholm Hlth Care Serv, Stockholm, Sweden..
    Chang, Zheng
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden..
    Larsson, Henrik
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Örebro Univ, Sch Med Sci, Örebro, Sweden..
    D'Onofrio, Brian M.
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA..
    Lichtenstein, Paul
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden..
    Sidorchuk, Anna
    Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden.;Stockholm Hlth Care Serv, Stockholm, Sweden..
    Fernandez de la Cruz, Lorena
    Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden.;Stockholm Hlth Care Serv, Stockholm, Sweden..
    Serious Transport Accidents in Tourette Syndrome or Chronic Tic Disorder2021In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 36, no 1, p. 188-195Article in journal (Refereed)
    Abstract [en]

    Background It is unknown whether individuals with tic disorders are at increased risk for serious transport accidents. Objectives The aim of this study was to investigate the risk for injuries or death caused by transport and motor vehicle accidents in individuals with Tourette syndrome or chronic tic disorder. Methods This population-based, sibling-controlled cohort study included all individuals aged >= 18 years living in Sweden between 1997 and 2013 (N = 6,127,290). A total of 3449 individuals had a registered diagnosis of Tourette syndrome or chronic tic disorder in the Swedish National Patient Register. We also identified 2191 families with full siblings discordant for tic disorders. Cox proportional hazards regression modeling was used to estimate the risk for injuries or deaths as a result of transport accidents in individuals with a lifetime diagnosis of Tourette syndrome or chronic tic disorder compared with unexposed individuals and siblings. Results Individuals with tic disorders had a higher risk for transport injuries or death compared with the general population (adjusted hazard ratio, 1.50 [95% confidence interval: 1.33-1.69]) and their unaffected siblings (adjusted hazard ratio, 1.41 [95% confidence interval: 1.18-1.68]). The risks were similar across sexes. The exclusion of most psychiatric comorbidities did not alter the magnitude of the estimates. However, the risks were no longer significant after exclusion of individuals with comorbid attention deficit hyperactivity disorder. Conclusions The marginally increased risk for serious transport accidents in tic disorders is mainly driven by attention deficit hyperactivity disorder comorbidity. Improved detection and management of attention deficit hyperactivity disorder symptoms in this patient group are warranted. (c) 2020 The Authors.Movement Disorderspublished by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.

    Download full text (pdf)
    fulltext
  • 6. Meppelink, Anne Marthe
    et al.
    Nyman, Rickard
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Radiology.
    van Laar, Teus
    Drent, Martje
    Prins, Ted
    Leenders, Klaus Leonhard
    Transcutaneous Port for Continuous Duodenal Levodopa/Carbidopa Administration in Parkinson's Disease2011In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 26, no 2, p. 331-334Article in journal (Refereed)
    Abstract [en]

    Motor fluctuations in Parkinson's disease (PD) can be reduced by intraduodenal infusion of levodopa-carbidopa (Duodopa®) via percutaneous endoscopic gastrojejunostomy (PEG). We applied the transcutaneous soft-tissue anchored titanium port (T-port) in 15 PD patients with motor fluctuations; 7 Duodopa-naive (non-PEG), and 8 previously receiving Duodopa (former-PEG). Motor scores (UPDRS-III) and quality of life (QOL, PDQ-8) were assessed at baseline and 6 month follow-up. Six patients had local irritation shortly after implantation, persisting in one patient at 6 month follow-up, which led to explantation. After having finished the protocol, four T-ports were explanted in total. UPDRS-III and PDQ-8 scores improved moderately in the non-PEG patients, but remained similar in the former-PEG users. Two former-PEG users developed polyneuropathy. No obstructions, retractions, or leakages occurred. Technical and hygienic properties of the T-port were preferred by most patients. The T-port seems to be suitable for most PD patients qualifying for Duodopa therapy, although local infection may lead to explantation during longer-term follow-up.

  • 7.
    Niemelä, Valter
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Landtblom: Neurology.
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Landtblom: Neurology.
    Nyholm, Dag
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Landtblom: Neurology.
    Kneider, Maria
    Institute of Neuroscience and Physiology; Clinical Neuroscience, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
    Constantinescu, Radu
    Institute of Neuroscience and Physiology; Clinical Neuroscience, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
    Paucar, Martin
    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
    Svenningsson, Per
    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
    Abujrais, Sandy
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Landtblom: Neurology.
    Shevchenko, Ganna
    Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - BMC, Analytical Chemistry.
    Bergquist, Jonas
    Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - BMC, Analytical Chemistry.
    Sundblom, Jimmy
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Enblad: Neurosurgery.
    Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease2021In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 36, no 2, p. 481-491Article in journal (Refereed)
    Abstract [en]

    OBJECTIVE: Identifying molecular changes that contribute to the onset and progression of Huntington's disease (HD) is of importance for the development and evaluation of potential therapies.

    METHODS: We conducted an unbiased mass-spectrometry proteomic analysis on the cerebrospinal fluid of 12 manifest HD patients (ManHD), 13 pre-manifest (preHD), and 38 controls. A biologically plausible and significant possible biomarker was validated in samples from a separate cohort of patients and controls consisting of 23 ManHD patients and 23 controls.

    RESULTS: In ManHD compared to preHD, 10 proteins were downregulated and 43 upregulated. Decreased levels of proenkephalin (PENK) and transthyretin were closely linked to HD symptom severity, whereas levels of 15 upregulated proteins were associated with symptom severity. The decreased PENK levels were replicated in the separate cohort where absolute quantitation was performed.

    CONCLUSIONS: We hypothesize that declining PENK levels reflect the degeneration of medium spiny neurons (MSNs) that produce PENK and that assays for PENK may serve as a surrogate marker for the state of MSNs in HD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

    Download full text (pdf)
    fulltext
  • 8.
    Nyholm, Dag
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Kowalski, Jan
    Aquilonius, Sten-Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease2004In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 19, no 4, p. 446-451Article in journal (Refereed)
    Abstract [en]

    Abstract

    Frequent assessment of the symptoms in Parkinson's disease (PD) is important in both clinical and experimental settings, especially when motor fluctuations are present. Patient diaries are increasingly used in studies, allowing patients to stay in their home environments. However, traditional paper diaries may not reflect reality because of a lack in compliance or retrospective data entries. This study presents a comparison between paper diaries and a new method, real-time data capture with a hand-held computer (electronic diary). Twenty patients with PD diagnosed at least 5 years previously were randomly assigned to use either a paper diary or an electronic diary on 8 days during 1 month. Questions were answered every 2 hours over a 12-hour period on each day. Median compliance was 88% with the electronic diary and 98% with the paper diary, although strict compliance to the scheduled times by patients using the paper diary was 78%. Neither age nor earlier experience with computers affected the patient's ability to use the electronic diary. Electronic diaries can be used for self-assessment of PD symptoms. The real-time feature provides fast access to clean data with knowledge of true compliance.

  • 9. Pal, Gian
    et al.
    Cook, Lola
    Schulze, Jeanine
    Verbrugge, Jennifer
    Alcalay, Roy N
    Merello, Marcelo
    Sue, Carolyn M
    Bardien, Soraya
    Bonifati, Vincenzo
    Chung, Sun Ju
    Foroud, Tatiana
    Gatto, Emilia
    Hall, Anne
    Hattori, Nobutaka
    Lynch, Tim
    Marder, Karen
    Mascalzoni, Deborah
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Novaković, Ivana
    Thaler, Avner
    Raymond, Deborah
    Salari, Mehri
    Shalash, Ali
    Suchowersky, Oksana
    Mencacci, Niccolò E
    Simuni, Tanya
    Saunders-Pullman, Rachel
    Klein, Christine
    Genetic Testing in Parkinson's Disease.2023In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 38, no 8, p. 1384-1396Article in journal (Refereed)
    Abstract [en]

    Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct-to-consumer settings. Although the potential utility of clinical testing is expanding, there are currently no proven gene-targeted therapies, but clinical trials are underway. Furthermore, genetic testing practices vary widely, as do knowledge and attitudes of relevant stakeholders. The specter of testing mandates financial, ethical, and physician engagement, and there is a need for guidelines to help navigate the myriad of challenges. However, to develop guidelines, gaps and controversies need to be clearly identified and analyzed. To this end, we first reviewed recent literature and subsequently identified gaps and controversies, some of which were partially addressed in the literature, but many of which are not well delineated or researched. Key gaps and controversies include: (1) Is genetic testing appropriate in symptomatic and asymptomatic individuals without medical actionability? (2) How, if at all, should testing vary based on ethnicity? (3) What are the long-term outcomes of consumer- and research-based genetic testing in presymptomatic PD? (4) What resources are needed for clinical genetic testing, and how is this impacted by models of care and cost-benefit considerations? Addressing these issues will help facilitate the development of consensus and guidelines regarding the approach and access to genetic testing and counseling. This is also needed to guide a multidisciplinary approach that accounts for cultural, geographic, and socioeconomic factors in developing testing guidelines. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • 10.
    Papathanou, Maria
    et al.
    Abbott Healthcare Products B.V., Weesp, The Netherlands.
    van der Laan, Rika
    Abbott Healthcare Products B.V., Weesp, the Netherlands.
    Jenner, Peter
    Rose, Sarah
    McCreary, Andrew C
    Abbott Healthcare Products B.V., Weesp, the Netherlands..
    Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats2013In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 28, no 8, p. 1072-1079Article in journal (Refereed)
    Abstract [en]

    The short duration of effect of levodopa is linked to pulsatile stimulation of striatal dopamine receptors and dyskinesia induction. However, the recent introduction of intraduodenal (i.d.) infusions and novel oral controlled release formulations of l-dopa may prevent dyskinesia induction and reduce the severity of established involuntary movements. We have compared the effects of twice-daily intraperitoneal (i.p.) administration and daily i.d. infusion of l-dopa on the induction and expression of abnormal involuntary movements in 6-hydroxydopamine (6-OHDA)-lesioned rats. Animals were treated with either twice-daily i.p. administration of l-dopa/carbidopa (7.85/12.5 mg/kg) or an 8-hour i.d. infusion of l-dopa/carbidopa (20/5 mg/mL; infusion rate: 0.04 mL/h) for 14 days, after which treatments were switched between groups and continued for a further 14 days. Pulsatile i.p. administration of l-dopa induced moderate to severe abnormal involuntary movements, which gradually increased in severity over the 14 days, but i.d. infusion of l-dopa induced abnormal involuntary movements of a similar severity. Switching from continuous i.d. to pulsatile i.p. administration of l-dopa continued to provoke severe abnormal involuntary movements expression. Switching from pulsatile i.p. to continuous i.d. l-dopa administration did not alter the peak abnormal involuntary movement severity but tended to reduce their duration. Treatment with less pulsatile l-dopa administration using i.d. infusion does not reduce the risk of the appearance of dyskinesia. By contrast, the duration of established dyskinesia can be reduced by more continuous l-dopa delivery in agreement with clinical experience

  • 11.
    Sasikumar, Sanskriti
    et al.
    Univ Toronto, Div Neurol, Toronto, ON, Canada.;Toronto Western Hosp, UHN, Edmond J Safra Program Parkinsons Dis & Morton &, Toronto, ON, Canada..
    Ingelsson, Martin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics. Univ Hlth Network, Krembil Brain Inst, Toronto, ON, Canada.;Univ Toronto, Dept Med, Toronto, ON, Canada.;Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada..
    Targeted Gene Therapy to Treat Disorders of the Central Nervous System2022In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 37, no 5, p. 892-892, article id 29017Article in journal (Other academic)
  • 12. Saunders-Pullman, Rachel
    et al.
    Raymond, Deborah
    Ortega, Roberto A
    Shalash, Ali
    Gatto, Emilia
    Salari, Mehri
    Markgraf, Maggie
    Alcalay, Roy N
    Mascalzoni, Deborah
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Centre for Research Ethics and Bioethics.
    Mencacci, Niccolò E
    Bonifati, Vincenzo
    Merello, Marcelo
    Chung, Sun Ju
    Novakovic, Ivana
    Bardien, Soraya
    Pal, Gian
    Hall, Anne
    Hattori, Nobutaka
    Lynch, Timothy
    Thaler, Avner
    Sue, Carolyn M
    Foroud, Tatiana
    Verbrugge, Jennifer
    Schulze, Jeanine
    Cook, Lola
    Marder, Karen
    Suchowersky, Oksana
    Klein, Christine
    Simuni, Tatyana
    International Genetic Testing and Counseling Practices for Parkinson's Disease.2023In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 38, no 8, p. 1527-1535Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: There is growing clinical and research utilization of genetic testing in Parkinson's disease (PD), including direct-to-consumer testing.

    OBJECTIVES: The aim is to determine the international landscape of genetic testing in PD to inform future worldwide recommendations.

    METHODS: A web-based survey assessing current practices, concerns, and barriers to genetic testing and counseling was administered to the International Parkinson and Movement Disorders Society membership.

    RESULTS: Common hurdles across sites included cost and access to genetic testing, and counseling, as well as education on genetic counseling. Region-dependent differences in access to and availability of testing and counseling were most notable in Africa. High-income countries also demonstrated heterogeneity, with European nations more likely to have genetic testing covered through insurance than Pan-American and Asian countries.

    CONCLUSIONS: This survey highlights not only diversity of barriers in different regions but also the shared and highly actionable needs for improved education and access to genetic counseling and testing for PD worldwide. © 2023 International Parkinson and Movement Disorder Society.

  • 13.
    Senek, Marina
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Nielsen, Elisabet I.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
    Nyholm, Dag
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study2017In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 32, no 2, p. 283-286Article in journal (Refereed)
    Abstract [en]

    BackgroundThe addition of oral entacapone to levodopa-carbidopa intestinal gel treatment leads to less conversion of levodopa to 3-O-methyldopa, thereby increasing levodopa plasma concentration. The objective of this study was to compare systemic levodopa exposure of the newly developed levodopa-entacapone-carbidopa intestinal gel after a 20% dose reduction with levodopa exposure after the usual levodopa-carbidopa intestinal gel dose in a randomized crossover trial in advanced Parkinson's disease patients. MethodsIn this 48-hour study, 11 patients treated with levodopa-carbidopa intestinal gel were randomized to a treatment sequence. Blood samples were drawn at prespecified times, and patient motor function was assessed according to the treatment response scale. ResultsSystemic exposure of levodopa did not differ significantly between treatments (ratio, 1.10 [95% confidence interval, 0.951-1.17]). Treatment response scale scores did not significantly differ between treatments (P=0.84). ConclusionsLevodopa-entacapone-carbidopa intestinal gel allowed a lower amount of levodopa administration and was well tolerated. Long-term studies are needed to confirm the results.

  • 14.
    Svenningsson, Per
    et al.
    Karolinska Inst, Dept Clin Neurosci, Sect Neurol, Stockholm, Sweden.
    Odin, Per
    Lund Univ, Dept Clin Sci Lund, Div Neurol, Lund, Sweden.
    Dizdar, Nil
    Linköping Univ, Dept Clin & Expt Med, Linköping, Sweden.
    Johansson, Anders
    Karolinska Inst, Dept Clin Neurosci, Sect Neurol, Stockholm, Sweden.
    Grigoriou, Sotirios
    Lund Univ, Dept Clin Sci Lund, Div Neurol, Lund, Sweden.
    Tsitsi, Panagiota
    Karolinska Inst, Dept Clin Neurosci, Sect Neurol, Stockholm, Sweden.
    Wictorin, Klas
    Helsingborg Hosp, Dept Neurol, Helsingborg, Sweden.
    Bergquist, Filip
    Univ Gothenburg, Sahlgrenska Acad, Dept Pharmacol, Gothenburg, Sweden.
    Nyholm, Dag
    Rinne, Juha
    Clin Res Serv Turku Oy, Turku, Finland; Turku Univ Hosp, Div Clin Neurosci, Turku, Finland.
    Hansson, Fredrik
    Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Economics.
    Sonesson, Clas
    Integrat Res Labs AB, Gothenburg, Sweden.
    Tedroff, Joakim
    Karolinska Inst, Dept Clin Neurosci, Sect Neurol, Stockholm, Sweden; Integrat Res Labs AB, Gothenburg, Sweden.
    A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia2020In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 35, no 6, p. 1046-1054Article in journal (Refereed)
    Abstract [en]

    Background

    IRL752 is a novel small‐molecule compound that acts to regioselectively enhance norepinephrine, dopamine, and acetylcholine neurotransmission in the cerebral cortex.

    Objective

    The primary objective of the trial was to investigate the safety and tolerability of IRL752 in patients with Parkinson's disease and dementia.

    Methods

    Patients with Parkinson's disease and dementia were randomized to IRL752 or placebo treatment (3:1 ratio) for 28 days. The study drug was given as an adjunct treatment to the patients’ regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days after which the dose was kept stable for an additional 14 days.

    Results

    A total of 32 patients were randomized to treatment, and 29 patients completed the 4‐week treatment. Adverse events were generally mild and transient and were mostly reported during the dose titration phase. There were 2 serious adverse events, and none of them were related to the experimental treatment. The average dose achieved in the stable dose phase was 600 mg daily, yielding a 2‐hour postdose plasma concentration of about 4 μM on day 28. Exploratory assessment of secondary outcomes indicated efficacy for symptoms and signs known to be poorly responsive to levodopa.

    Conclusions

    IRL752 appears to be safe and well tolerated for a 4‐week treatment in patients with Parkinson's disease and dementia.

  • 15. Yang, Fei
    et al.
    Wolk, Alicja
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Orthopaedics.
    Håkansson, Niclas
    Pedersen, Nancy L
    Wirdefeldt, Karin
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.2017In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 32, no 11, p. 1631-1636Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: A neuroprotective effect of dietary antioxidants on Parkinson's disease (PD) risk has been suggested, but epidemiological evidence is limited.

    OBJECTIVES: To examine the associations between intake of dietary antioxidant vitamins and total antioxidant capacity and risk of PD.

    METHODS: We prospectively assessed the relationships of dietary antioxidant vitamins C and E, ß-carotene, and total antioxidant capacity with PD risk in two population-based cohorts (38,937 women and 45,837 men).

    RESULTS: During a mean 14.9-year follow-up period, 1,329 PD cases were identified. Dietary intake of ß-carotene was associated with a lower risk of PD (hazard ratio: 0.86; 95% confidence interval: 0.78-0.95; Ptrend  < 0.01 for women and hazard ratio: 0.91; 95% confidence interval: 0.84-0.99; Ptrend  = 0.05 for men). An inverse association between dietary vitamin E and PD risk was found in women (hazard ratio: 0.87; 95% confidence interval: 0.79-0.96; Ptrend  = 0.02). Dietary intake of vitamin C was inversely associated with PD risk in women at borderline significance (hazard ratio: 0.91; 95% confidence interval: 0.83-1.00; Ptrend  = 0.04). There was no association between dietary total antioxidant capacity and PD risk in either women (hazard ratio: 0.93; 95% confidence interval: 0.84-1.02; Ptrend  = 0.35) or men (hazard ratio: 1.00; 95% confidence interval: 0.93-1.07; Ptrend  = 0.97).

    CONCLUSION: Intake of dietary vitamin E and ß-carotene was associated with a lower risk of PD. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

1 - 15 of 15
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf